2013
Haemoglobin recovery among HIV-1 infected patients on zidovudine-based antiretroviral therapy and other regimens in north-central Nigeria
Parrish DD, Blevins M, Megazzini KM, Shepherd BE, Mohammed MY, Wester CW, Vermund SH, Aliyu MH. Haemoglobin recovery among HIV-1 infected patients on zidovudine-based antiretroviral therapy and other regimens in north-central Nigeria. International Journal Of STD & AIDS 2013, 25: 355-359. PMID: 24104694, PMCID: PMC4385388, DOI: 10.1177/0956462413506887.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemiaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDrug Therapy, CombinationFemaleHemoglobinsHIV InfectionsHumansLinear ModelsMaleMiddle AgedNigeriaRetrospective StudiesReverse Transcriptase InhibitorsRural PopulationSocioeconomic FactorsTime FactorsTreatment OutcomeZidovudineConceptsBaseline hemoglobin levelCombination antiretroviral therapyHemoglobin levelsAntiretroviral therapyHemoglobin recoveryNon-pregnant adult patientsUse of zidovudineZidovudine-containing regimenZidovudine-containing regimensNorth Central NigeriaGroup of patientsRural North-Central NigeriaMeasures of hemoglobinZidovudine useBaseline hemoglobinAdult patientsMedian hemoglobinHemoglobin responseHIV-1PatientsZidovudineHemoglobin dataHemoglobinRegimensTherapy
2007
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine
Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, Zulu I, Kankasa C, Wilfert C, Weidle PJ, Vermund SH, Stringer J. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007, 21: 957-964. PMID: 17457089, PMCID: PMC2745970, DOI: 10.1097/qad.0b013e32810996b2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountDrug Administration ScheduleEpidemiologic MethodsFemaleHIV InfectionsHumansInfectious Disease Transmission, VerticalNevirapinePregnancyPregnancy Complications, InfectiousReverse Transcriptase InhibitorsTreatment FailureTreatment OutcomeConceptsSingle-dose nevirapineClinical treatment failureCD4 cell responseAntiretroviral therapyTreatment failureNVP exposureTreatment outcomesCell responsesShort-term treatment outcomesPrior exposureChild HIV transmissionPrevention of motherCD4 cell changesPoor treatment outcomesNon-nucleoside reverseSignificant differencesWorld Health Organization guidelinesHealth Organization guidelinesART initiationCohort evaluationMultivariable analysisHIV transmissionHIV treatmentRisk factorsImmune response
2006
Millions of Life-Years Saved with Potent Antiretroviral Drugs in the United States: A Celebration, with Challenges
Vermund SH. Millions of Life-Years Saved with Potent Antiretroviral Drugs in the United States: A Celebration, with Challenges. The Journal Of Infectious Diseases 2006, 194: 1-5. PMID: 16741874, DOI: 10.1086/505154.Peer-Reviewed Original Research
2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
Stringer J, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003, 17: 1659-1665. PMID: 12853748, PMCID: PMC2745973, DOI: 10.1097/00002030-200307250-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBreast FeedingDrug Administration ScheduleFemaleHIV InfectionsHIV SeropositivityHumansInfant, NewbornInfectious Disease Transmission, VerticalLabor, ObstetricNevirapineObstetric Labor ComplicationsPregnancyPregnancy Complications, InfectiousProspective StudiesReverse Transcriptase InhibitorsRisk FactorsTime FactorsConceptsPerinatal HIV transmissionHIV transmissionInfant HIV infection statusNeonatal single-dose nevirapineMaternal drug doseSingle-dose nevirapineHIV infection statusProspective cohort studyPerinatal transmission rateOnset of laborMain outcome measuresMean drug concentrationWeeks of lifeRisk of transmissionNVP levelsNVP prophylaxisNVP syrupObstetrical clinicPerinatal transmissionCohort studyOral doseViral loadPregnant womenPolymerase chain reactionRisk factorsComparison of Two Strategies for Administering Nevirapine to Prevent Perinatal HIV Transmission in High-Prevalence, Resource-Poor Settings
Stringer JS, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, Kumwenda-Phiri R, Vermund SH. Comparison of Two Strategies for Administering Nevirapine to Prevent Perinatal HIV Transmission in High-Prevalence, Resource-Poor Settings. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2003, 32: 506-513. PMID: 12679702, PMCID: PMC2745994, DOI: 10.1097/00126334-200304150-00007.Peer-Reviewed Original ResearchConceptsHigh-prevalence settingsClinic AClinic BVCT servicesPrevent Perinatal HIV TransmissionPerinatal HIV acquisitionPerinatal HIV preventionPerinatal HIV transmissionKnowledge of serostatusResource-poor settingsNevirapine therapyNVP therapyHIV acquisitionHIV testingHIV statusHIV transmissionPregnant womenCord bloodHIV preventionHigh prevalenceInfant deathUniversal therapyClinicTherapyMaternal reports
1999
Rapid Communication CCR5 Genotype and Resistance to Vertical Transmission of HIV-1
Philpott S, Burger H, Charbonneau T, Grimson R, Vermund S, Visosky A, Nachman S, Kovacs A, Tropper P, Frey H, Weiser B. Rapid Communication CCR5 Genotype and Resistance to Vertical Transmission of HIV-1. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 21: 189-193. PMID: 10421241, DOI: 10.1097/00126334-199907010-00002.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAnti-HIV AgentsChildFemaleGenotypeHIV InfectionsHIV-1HumansImmunity, InnateInfectious Disease Transmission, VerticalProspective StudiesReceptors, CCR5Reverse Transcriptase InhibitorsZidovudineConceptsHIV-1 infectionHIV-1Vertical transmissionCCR5 genotypeHIV-1 infection statusHIV-1 vertical transmissionHIV-1-infected mothersPrimary HIV-1 infectionMacrophage-tropic strainsAfrican AmericansParenteral transmissionUninfected childrenChild transmissionInfected childrenInfected mothersInfected womenDelta32 mutationCCR5 receptorInfection statusWhite childrenCCR5MothersChildrenHomozygous genotypeAdditional strategiesPrevention of Mother-to-Child Transmission of HIV in Thailand: Physicians' Attitudes on Zidovudine Use, Pregnancy Termination, and Willingness to Provide Care.
Stringer J, Stringer E, Phanuphak P, Jetwana P, Reinprayoon D, Funkhouser E, Vermund S. Prevention of Mother-to-Child Transmission of HIV in Thailand: Physicians' Attitudes on Zidovudine Use, Pregnancy Termination, and Willingness to Provide Care. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 21: 217-222. PMID: 10421245, DOI: 10.1097/00126334-199907010-00006.Peer-Reviewed Original ResearchConceptsZDV prophylaxisZidovudine usePregnant womenPregnancy terminationPrevention of motherPredictors of failureObstetrics/gynecologyLogistic regression modelsAntiretroviral therapyChild transmissionCesarean deliveryObstetric providersVaginal deliveryMultivariable analysisPelvic examinationMale genderPhysicians' attitudesHIVPhysician educationElective abortionPatientsWomenThai physiciansRegular mailProphylaxis